JP2014528411A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014528411A5 JP2014528411A5 JP2014533335A JP2014533335A JP2014528411A5 JP 2014528411 A5 JP2014528411 A5 JP 2014528411A5 JP 2014533335 A JP2014533335 A JP 2014533335A JP 2014533335 A JP2014533335 A JP 2014533335A JP 2014528411 A5 JP2014528411 A5 JP 2014528411A5
- Authority
- JP
- Japan
- Prior art keywords
- delivery composition
- agent
- diagnostic
- therapeutic
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims description 72
- 230000001225 therapeutic effect Effects 0.000 claims description 47
- 108091034117 Oligonucleotide Proteins 0.000 claims description 38
- 239000000032 diagnostic agent Substances 0.000 claims description 37
- 229940039227 diagnostic agent Drugs 0.000 claims description 33
- 239000003795 chemical substances by application Substances 0.000 claims description 31
- 239000002105 nanoparticle Substances 0.000 claims description 28
- 125000005647 linker group Chemical group 0.000 claims description 26
- 230000008685 targeting Effects 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 20
- 230000002163 immunogen Effects 0.000 claims description 20
- 229940124597 therapeutic agent Drugs 0.000 claims description 20
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 16
- 230000000295 complement effect Effects 0.000 claims description 14
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 150000002632 lipids Chemical class 0.000 claims description 9
- 108091023037 Aptamer Proteins 0.000 claims description 8
- 239000002872 contrast media Substances 0.000 claims description 8
- 239000002502 liposome Substances 0.000 claims description 8
- 230000002285 radioactive effect Effects 0.000 claims description 8
- 108020003175 receptors Proteins 0.000 claims description 8
- 102000005962 receptors Human genes 0.000 claims description 8
- 239000004615 ingredient Substances 0.000 claims description 7
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 6
- 229940123237 Taxane Drugs 0.000 claims description 6
- 229960004562 carboplatin Drugs 0.000 claims description 6
- 190000008236 carboplatin Chemical compound 0.000 claims description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 6
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 6
- 229960004316 cisplatin Drugs 0.000 claims description 6
- 229960004679 doxorubicin Drugs 0.000 claims description 6
- 229960002949 fluorouracil Drugs 0.000 claims description 6
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 6
- 229960005277 gemcitabine Drugs 0.000 claims description 6
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 6
- 229960001756 oxaliplatin Drugs 0.000 claims description 6
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 6
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims description 4
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims description 4
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 4
- 102000004161 Claudin-4 Human genes 0.000 claims description 4
- 108090000601 Claudin-4 Proteins 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 4
- -1 FOL1R Proteins 0.000 claims description 4
- 229930186217 Glycolipid Natural products 0.000 claims description 4
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims description 4
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 4
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 4
- 108010008707 Mucin-1 Proteins 0.000 claims description 4
- 102100034256 Mucin-1 Human genes 0.000 claims description 4
- 108010008699 Mucin-4 Proteins 0.000 claims description 4
- 102100022693 Mucin-4 Human genes 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 102100021010 Nucleolin Human genes 0.000 claims description 4
- 108700020796 Oncogene Proteins 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- 102000008858 Somatostatin receptor 4 Human genes 0.000 claims description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 4
- 125000000524 functional group Chemical group 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 4
- 239000000693 micelle Substances 0.000 claims description 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 4
- 108010044762 nucleolin Proteins 0.000 claims description 4
- 150000003904 phospholipids Chemical class 0.000 claims description 4
- 229920005646 polycarboxylate Polymers 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 229920001451 polypropylene glycol Polymers 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 108010064556 somatostatin receptor subtype-4 Proteins 0.000 claims description 4
- 150000003408 sphingolipids Chemical class 0.000 claims description 4
- 102000001253 Protein Kinase Human genes 0.000 claims description 3
- 208000021841 acute erythroid leukemia Diseases 0.000 claims description 3
- 235000012000 cholesterol Nutrition 0.000 claims description 3
- 238000003384 imaging method Methods 0.000 claims description 3
- 108060006633 protein kinase Proteins 0.000 claims description 3
- 239000000232 Lipid Bilayer Substances 0.000 claims description 2
- 108090001030 Lipoproteins Proteins 0.000 claims description 2
- 102000004895 Lipoproteins Human genes 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 229920001400 block copolymer Polymers 0.000 claims description 2
- 239000000412 dendrimer Substances 0.000 claims description 2
- 229920000736 dendritic polymer Polymers 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 239000002353 niosome Substances 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 229920000575 polymersome Polymers 0.000 claims description 2
- 239000002096 quantum dot Substances 0.000 claims description 2
- 150000001841 cholesterols Chemical class 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 230000000925 erythroid effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161541797P | 2011-09-30 | 2011-09-30 | |
| US61/541,797 | 2011-09-30 | ||
| PCT/US2012/057642 WO2013049405A1 (en) | 2011-09-30 | 2012-09-27 | Remote assembly of targeted nanoparticles using complementary oligonucleotide linkers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014528411A JP2014528411A (ja) | 2014-10-27 |
| JP2014528411A5 true JP2014528411A5 (https=) | 2015-10-08 |
Family
ID=47045165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014533335A Withdrawn JP2014528411A (ja) | 2011-09-30 | 2012-09-27 | 相補的オリゴヌクレオチドリンカーを用いる標的化ナノ粒子の遠隔アセンブリ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20140234217A1 (https=) |
| EP (1) | EP2760476A1 (https=) |
| JP (1) | JP2014528411A (https=) |
| KR (1) | KR20140069269A (https=) |
| CN (1) | CN104039355A (https=) |
| BR (1) | BR112014007501A2 (https=) |
| CA (1) | CA2850198A1 (https=) |
| IL (1) | IL231767A0 (https=) |
| WO (1) | WO2013049405A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2773327A4 (en) | 2011-11-02 | 2015-06-03 | Univ California | REPROGRAMMING CELL ADHESION |
| WO2016004043A1 (en) * | 2014-06-30 | 2016-01-07 | Blend Therapeutics, Inc. | Targeted conjugates and particles and formulations thereof |
| WO2016160822A1 (en) * | 2015-03-30 | 2016-10-06 | Verily Life Sciences Llc | Functionalized nanoparticles, methods and in vivo diagnostic system |
| KR101713118B1 (ko) * | 2015-08-28 | 2017-03-10 | 서강대학교산학협력단 | 세포외기질 전달용 리포솜 |
| KR20180112060A (ko) | 2016-02-23 | 2018-10-11 | 타베다 세라퓨틱스, 인코포레이티드 | Hsp90 표적화된 접합체 및 이의 입자 및 제형 |
| TWI772766B (zh) * | 2019-10-09 | 2022-08-01 | 國立清華大學 | 奈米粒子及其製備方法與用途 |
| WO2021242933A1 (en) * | 2020-05-27 | 2021-12-02 | Academia Sinica | Monocyte-specific aptamers and uses thereof for enhancing drug delivery to cancer |
| CN113244415A (zh) * | 2021-05-10 | 2021-08-13 | 吉林大学 | 一种纳米造影剂及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0786469B1 (en) | 1990-06-11 | 2006-03-01 | Gilead Sciences, Inc. | Methods of use of nucleic acid ligands |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| US5718915A (en) * | 1994-10-31 | 1998-02-17 | Burstein Laboratories, Inc. | Antiviral liposome having coupled target-binding moiety and hydrolytic enzyme |
| US7833992B2 (en) * | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
| DE10049074A1 (de) | 2000-10-02 | 2002-04-18 | Andreas Kage | Verfahren zur Selektion hochaffin an ein Target bindender Nukleinsäuren |
| KR20070101227A (ko) | 2004-09-07 | 2007-10-16 | 아케믹스 코포레이션 | 폰 빌레브란트 인자에 대한 앱타머 및 이의 혈전증치료제로서의 용도 |
| EP2618846A1 (en) * | 2010-09-24 | 2013-07-31 | Mallinckrodt LLC | Aptamer conjugates for targeting of therapeutic and/or diagnostic nanocarriers |
-
2012
- 2012-09-27 WO PCT/US2012/057642 patent/WO2013049405A1/en not_active Ceased
- 2012-09-27 JP JP2014533335A patent/JP2014528411A/ja not_active Withdrawn
- 2012-09-27 CA CA2850198A patent/CA2850198A1/en not_active Abandoned
- 2012-09-27 BR BR112014007501A patent/BR112014007501A2/pt not_active IP Right Cessation
- 2012-09-27 KR KR1020147011173A patent/KR20140069269A/ko not_active Withdrawn
- 2012-09-27 US US14/348,522 patent/US20140234217A1/en not_active Abandoned
- 2012-09-27 EP EP12775096.6A patent/EP2760476A1/en not_active Withdrawn
- 2012-09-27 CN CN201280059038.5A patent/CN104039355A/zh active Pending
-
2014
- 2014-03-27 IL IL231767A patent/IL231767A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014528411A5 (https=) | ||
| JP2013538829A5 (https=) | ||
| Guimaraes et al. | Nanoparticles for immune cytokine TRAIL-based cancer therapy | |
| Wang et al. | Diagnostic imaging and therapeutic application of nanoparticles targeting the liver | |
| US10568970B2 (en) | Theranostic compositions and uses thereof | |
| Wang et al. | Multifunctional chitosan magnetic-graphene (CMG) nanoparticles: a theranostic platform for tumor-targeted co-delivery of drugs, genes and MRI contrast agents | |
| Khan et al. | Nanoparticles for biomedical applications: An overview | |
| Peng et al. | Polymeric multifunctional nanomaterials for theranostics | |
| Zhang et al. | The evolution of gadolinium based contrast agents: from single-modality to multi-modality | |
| Babu et al. | Nanodrug delivery systems: a promising technology for detection, diagnosis, and treatment of cancer | |
| Kamaly et al. | Folate receptor targeted bimodal liposomes for tumor magnetic resonance imaging | |
| US9289505B2 (en) | Compositions and methods for delivering nucleic acid molecules and treating cancer | |
| Zhu et al. | pH‐responsive drug‐delivery systems | |
| Yang et al. | Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2 | |
| JP2014527071A5 (https=) | ||
| Kim et al. | Nanomedicine in cancer treatment | |
| KR101740895B1 (ko) | 뇌조직에 특이적으로 전달 가능한 뇌조직 표적화 펩티드와 키토산이 결합된 플루로닉 고분자를 포함하는 뇌표적 나노전달체 | |
| WO2016168197A1 (en) | Compositions for enhancing delivery of agents across the blood brain barrier and methods of use thereof | |
| US20210393523A1 (en) | Aromatic ring substituted amphiphilic polymers as drug delivery systems | |
| Zanganeh et al. | Immunoengineering in glioblastoma imaging and therapy | |
| Manikkath et al. | Nanoparticulate strategies for the delivery of miRNA mimics and inhibitors in anticancer therapy and its potential utility in oral submucous fibrosis | |
| KR20140069269A (ko) | 상보성 올리고뉴클레오티드 링커를 사용한 표적화된 나노입자들의 원격 조립 | |
| Choksi et al. | Functionalized nanoparticles targeting biomarkers for prostate cancer imaging and therapy | |
| CN113646003A (zh) | 多配体官能化的聚合物泡囊 | |
| JP2015502946A5 (https=) |